| Prev Close | 69.67 |
| Open | 70.00 |
| Day Low/High | 69.31 / 70.46 |
| 52 Wk Low/High | 56.56 / 73.34 |
| Volume | 7.73M |
Gilead Sciences, Inc. (GILD)
69.56
0.11
0.16
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1254.38B |
| Market Cap | 86.46B |
| P/E Ratio | 68.31 |
| Div & Yield | N.A. (N.A) |
Allergan Is a Blueprint for Gilead
At least, that's the case when it comes to a technical trade.
3 Takeover Candidates in the Drug Space
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
5 Toxic Stocks to Watch
Watch out for these stocks as we start 2017.
3 Takeover Candidates in the Drug Space
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Beaten-Down Gilead Is My Top 2017 Pick
Shares are dirt cheap as revenues and profits have grown.
Here's What to Look for at the J.P. Morgan Healthcare Conference
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
My Takeaways and Observations
I love gold. Trade of the Week -- short Apple at $116.15. (The SoftBank investment is a non-event). Dwyerama is chillin' and I am re-establishing my ProShares UltraShort S&P500 ETF long -- back in a revolutionary mindset. As January goes......
My Takeaways and Observations (3:30 p.m. Edition)
The markets started the day like Usain Bolt at the start of a 100-meter race. But, unlike Bolt, the finish wasn't as strong as the start. I thought one of the day's features was the reversal in bond yields, particularly after the good data. The...
Biotech Should Witness M&A's Return in 2017
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
My Takeaways and Observations
"Who you tryin' to get crazy with, 'ese? Don't you know I'm loco?..." -- Cypress Hill, Insane in the Brain 2017 will be the year of "The Dude." My favorite large-cap long Allergan and short Caterpillar for next year. AGN closed up by $4(!) wh...
Biotech Poised for Rebound
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
Biotech Poised for Rebound
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
My Takeaways and Observations (2:45 p.m. EST edition)
"First gear, it's all right (Honda, Honda, go faster, faster) Second gear, I'll lean right (Honda, Honda, go faster, faster) Third gear, hang on tight (Honda, Honda, go faster, faster) Faster, it's all right." -- Beach Boys, "Little Honda" With a b...
Expect Some Big-Cap Biotech Love in 2017
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...
2 Biotech Giants Poised for a Better 2017
Here's why Gilead and Celgene should finally reward their shareholders next year.
My Takeaways and Observations
"Everyone here likes the bounce." -- President-elect Donald Trump (said in a meeting today at Trump Tower with tech executives) A good day for the ursine crowd but not so good for the bullish cabal as they had a bad day -- for a change. (Yes, I am w...
Cramer: Rate-Hike Silver Linings Playbook Gets Dusted Off
There's a reason why FANG is back -- though it never really went away.
Gilead's Decline Appears to Be Ending
The long downtrend is looking mature.
My Takeaways and Observations
Was yesterday "FOMO" or something else? I waited and then moved on the volatility trade. "How many syllables Mario?" (A Putney Swope reference!) Wall Street is now a fear-free zone. Mark Hanson on negative homeowners' equity. Shorted ...
This May Be 2016's Top Stock-Selection Model
The 'Enterprise Value Growth and Income' stock-picking model should be quite effective in 2017, too.
I'm Buying Biotech on This Trump Scare
If the market is going to overreact to every new missive from Trump, I plan to take advantage.
Hold Your Breath When Diving for Deep Value
It can take many months or quarters before the market recognizes the value of a downtrodden name.
My Takeaways and Observations
"Well, they call you lady luck But there is room for doubt At times you have a very un-lady-like way Of running out..." -- Guys and Dolls, Luck Be A Lady (Frank Sinatra) Trump will not likely Make Twitter Great Again. I, bear. Explaining my pr...
My Takeaways and Observations
What a strange day -- maybe even ominous. This table tells it all. The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...
'Yuge' Sector Rotation Will Continue
What's in, what's out and who should thrive in the new political landscape.
Looking for Shorts (In All the Right Places)
In looking for shorts there is one important and underlying factor that governs my selection process: I try through rigorous analysis to identify sectors and companies with intermediate-term prospects that are deteriorating relative to consensus exp...
My Takeaways and Observations (3:30 p.m. Edition)
It may be time to embrace the contrary. First issue (!!): The Palm Beach Chronicles. My weekly (brief) technical review of the markets -- cooling off ahead? BTIG's Stockton is bullish and so, as I have expressed, are most others! Campbell ...
Some 'January Effect' Stock Picks
Small-caps could also benefit from abating tax-loss selling.
